Alnylam Pharmaceuticals (ALNY) Operating Income (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Operating Income of $268.6 million for Q1 2026, up 103.95% on a QoQ basis from $131.7 million in Q4 2025, and up 1386.07% year-over-year from $18.1 million in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Operating Income (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Operating Income history runs 18 years deep, the most recent figure standing at $268.6 million for Q1 2026.
- Quarterly Operating Income rose 1386.07% year-over-year to $268.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $752.1 million (up 751.92% YoY) and the FY2025 annual result came in at $501.6 million, up 383.56% from the prior year.
- Operating Income was $268.6 million for Q1 2026 at Alnylam Pharmaceuticals, up from $131.7 million in the prior quarter.
- Across five years, Operating Income topped out at $368.0 million in Q3 2025 and bottomed at -$258.0 million in Q3 2022.
- A 5-year average of -$27.9 million and a median of -$76.9 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income plunged 135.96% — and 2026, when it soared 1386.07%.
- Alnylam Pharmaceuticals' Operating Income stood at -$188.6 million in 2022, then soared by 38.28% to -$116.4 million in 2023, then increased by 9.66% to -$105.2 million in 2024, then surged by 225.26% to $131.7 million in 2025, then jumped by 103.95% to $268.6 million in 2026.
- Business Quant data shows ALNY's Operating Income at $268.6 million in Q1 2026, $131.7 million in Q4 2025, and $368.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 268.64 Mn |
| Dec 31, 2025 | 131.72 Mn |
| Sep 30, 2025 | 367.98 Mn |
| Jun 30, 2025 | -16.20 Mn |
| Mar 31, 2025 | 18.08 Mn |
| Dec 31, 2024 | -105.16 Mn |
| Sep 30, 2024 | -76.91 Mn |
| Jun 30, 2024 | 48.61 Mn |
| Mar 31, 2024 | -43.44 Mn |
| Dec 31, 2023 | -116.40 Mn |
| Sep 30, 2023 | 213.87 Mn |
| Jun 30, 2023 | -229.83 Mn |
| Mar 31, 2023 | -149.81 Mn |
| Dec 31, 2022 | -188.61 Mn |
| Sep 30, 2022 | -258.04 Mn |
| Jun 30, 2022 | -191.69 Mn |
| Mar 31, 2022 | -146.73 Mn |
| Dec 31, 2021 | -194.56 Mn |
| Sep 30, 2021 | -181.68 Mn |
| Jun 30, 2021 | -146.16 Mn |